Leveraging Science for Lifetime Medicine

From a one-man discovery to a passionate global drug development team working on the next generation of metabolic and inflammatory therapeutics

From Bench to Bedside

We leverage science to deliver effective, safe, and tolerable lifetime medicine for inflammatory diseases based on our deep understanding of drug research and development, breakthrough mechanisms of action, and global collaborations.

Pipeline
ARMOR Phase 3 Study
Jan. 11, 2022

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

Read More
Jan. 10, 2022

Galmed announces positive results of Phase 1 study of Amilo-5MER

Read More
Nov. 8, 2021

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

Read More